Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vascular Diseases 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pathologic Processes 1Paraproteinemias 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms, Glandular and Epithelial 1Multiple Myeloma 1Mullerian Mixed Tumor of Ovary 1Mouth Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Lymphatic Diseases 1Lung Neoplasms 1Lung Diseases 1

Interventions

Cytarabine 561Azacitidine 385venetoclax 311Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 187Busulfan 176Daunorubicin 155Idarubicin 151Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 73Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × ficlatuzumab × Clear all
NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

University of California, San Francisco

Phase 1 Terminated
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡